Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.74 |
| ▸ | MEN1 | O00255 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.74 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.74 |
| ▸ | RELA | Q04206 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285776 | 0.85 | RAB9A (0.74) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL6287741 | 0.82 | CDK2 (0.76) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL6371956 | 0.81 | MAPT (0.67) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL10253092 | 0.81 | SMN1; SMN2 (0.71) | RAB9AKMT2ASMN1; SMN2MEN1NFKB1 | |
| SCHEMBL10286991 | 0.80 | MMP3 (0.51) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL881769 | 0.78 | MEN1 (0.76) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL6285653 | 0.77 | RAB9A (0.63) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL6710960 | 0.77 | RAB9A (0.62) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL13401787 | 0.76 | RAB9A (0.60) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL5453617 | 0.76 | RAB9A (0.60) | RAB9AKMT2ASMN1; SMN2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | claimed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | claimed |
| US-9376430-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-06-28 | — | — | US | disclosed |
| US-9333193-B2 | Compositions and methods for treating tuberculosis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-8835644-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120010187-A1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-01-12 | — | — | US | disclosed |
| US-6863647-B2 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2005-03-08 | — | — | US | disclosed |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | disclosed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | RAB9A 2674/4885KMT2A 2751/4885SMN1; SMN2 2448/4885 |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | RAB9A 2674/4885KMT2A 2751/4885SMN1; SMN2 2448/4885 |
| US-20120010187-A1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | NMT1, MLEC, EPN1 | RAB9A 3418/4885KMT2A 4279/4885SMN1; SMN2 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.